<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262002</url>
  </required_header>
  <id_info>
    <org_study_id>V59P5</org_study_id>
    <secondary_id>2004-000195-13</secondary_id>
    <nct_id>NCT00262002</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants</brief_title>
  <official_title>A Phase II, Randomized, Open Label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory After Two or Three Doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants at 2, 3, 4 or 2, 4, 6 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, immunogenicity and induction of immune
      memory after two or three doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate
      Vaccine administered to healthy infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Vaccine</measure>
    <time_frame>Baseline and at 1 month after the 3 dose primary vaccination series</time_frame>
    <description>Immunogenicity was measured as the percentage of subjects with human serum bactericidal assay (hSBA) titers ≥ 1:4 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W and Y, at the baseline and 1 month after primary vaccination by groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:8 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Conjugate Vaccine</measure>
    <time_frame>Baseline and 1 month after the 3 dose primary vaccination series</time_frame>
    <description>Immunogenicity was measured by percentages of subjects With hSBA titers ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W and Y, at baseline and 1 month after primary vaccination by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers (GMTs) Following 3 Doses of MenACWY Ad+ Conjugate Vaccine</measure>
    <time_frame>Baseline and 1 month after the 3 dose primary vaccination series</time_frame>
    <description>Immunogenicity was measured as hSBA GMTs and associated 95% CI, against N meningitis serogroups A, C, W, and Y, at the baseline and 1 month after primary vaccination by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 Against N. Meningitidis Serogroups A, C, W, and Y Following 2 Doses of Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines</measure>
    <time_frame>Baseline and 1 month after second vaccination</time_frame>
    <description>Immunogenicity was measured as the percentages of subjects With hSBA titers ≥ 1:4 and ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, at Baseline and 1 month after second vaccination by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titer (GMTs) Following 2 Doses of MenACWY Ad+ and MenACWY Ad- Conjugate Vaccines</measure>
    <time_frame>Baseline and 1 month after second vaccination</time_frame>
    <description>Immunogenicity was measured as hSBA GMTs and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y at baseline and 1 month after second vaccination by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 Against N. Meningitidis Serogroups A, C, W &amp; Y After a Booster Dose of MenACWY Ad+ or Ad- Vaccine in a Subgroup of Subjects Following 2 or 3 Doses or MenACWY Ad+ or 2 Doses of MenACWY Ad- Vaccine</measure>
    <time_frame>at 12 months of age and 1 month after booster vaccination</time_frame>
    <description>Immunogenicity was measured as the percentages of subjects with hSBA ≥ 1:4 or ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after booster by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers (GMT) After a Booster Dose of MenACWY Ad+ or Ad- Vaccine Conjugate in a Subgroup of Subjects Following Either 2 or 3 Doses of MenACWY Ad+ Vaccine or 2 Doses of MenACWY Ad- Conjugate Vaccines</measure>
    <time_frame>at 12 months of age and 1 month after booster vaccination</time_frame>
    <description>Immunogenicity was measured as GMT and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after booster by group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroups A, C, W and Y Following 2 Doses of Novartis MenACWY Ad+ Vaccine, Novartis MenACWY Ad- Vaccine or Novartis Menjugate Vaccine</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>The persistence of immune response was measured as the percentages of subjects with hSBA ≥ 1:4 and ≥ 1:8 against N. Meningitidis serogroups A, C, W, and Y at 12 months of age by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers (GMTs) After 2 Doses of Novartis MenACWY Ad+ Vaccines, Novartis MenACWY Ad- Vaccine, or Novartis Menjugate Vaccine.</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>The persistence of immune response as measured by hSBA GMT and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroup A, C, W and Y Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>The persistence of immune response as measured by percentages of subjects with hSBA≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y, at 12 months by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers (GMTs) Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>The persistence of immune response as measured by hSBA GMTs and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y,at 12 months by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</measure>
    <time_frame>before challenge at 12 months of age and 1 month after PS challenge.</time_frame>
    <description>The induction of immunological memory was measured as percentages of subjects with hSBA ≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y , before challenge at 12 months of age and 1 month after PS challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers (GMTs) in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</measure>
    <time_frame>before challenge at 12 months of age and 1 month after PS challenge.</time_frame>
    <description>The induction of immunological memory was measured as hSBA Geometric Mean Titers (GMTs) and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y , before challenge at 12 months of age and 1 month after PS challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following Two Doses of Novartis MenACWY Ad+ or MenACWY Ad- Conjugate Vaccine</measure>
    <time_frame>Before challenge at 12 months of age and 1 month after PS challenge.</time_frame>
    <description>The Induction of immunological memory was measured as percentage of subjects with hSBA ≥ 1:4, hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, before challenge at 12 months and 1 month after PS challenge by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers (GMTs) in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following Two Doses of Novartis MenACWY Ad+ or MenACWY Ad- Conjugate Vaccine</measure>
    <time_frame>Before challenge at 12 months of age and 1 month after PS challenge.</time_frame>
    <description>Induction of immunological memory was measured by hSBA Geometric Mean Titers (GMTs) and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, before challenge at 12 months and 1 month after PS challenge by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 of MenACWY Ad+ Conjugate Vaccine</measure>
    <time_frame>Baseline and 1 month after the 2 or 3 dose primary vaccination series</time_frame>
    <description>The immunogenicity was measured as percentages of subject with hSBA≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, baseline and 1 month after 2 or 3 dose primary series by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 in Subjects Challenged With a Reduced Dose of a Licensed Meningococcal ACWY PS Vaccine Following 2 or 3 Doses of MenACWY Ad+ Conjugate Vaccine</measure>
    <time_frame>at 12 months of age and 1 month after PS challenge</time_frame>
    <description>The memory response was measured as percentages of subjects with hSBA ≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after PS challenge by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Antibody Response to Routine Vaccines (Hib, Diphtheria, Tetanus, Hepatitis B) When Routine Vaccines Are Given Concomitantly With Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines</measure>
    <time_frame>Baseline and 1 month after the 2 or 3 dose primary vaccination series</time_frame>
    <description>To assess the immunogenicity of routine vaccines when given concomitantly to Novartis MenACWY Ad+ or Novartis MenACWY Ad- conjugate vaccines. Hib, diphtheria, tetanus, pertussis will be evaluated as the first priority, followed by pneumococcus, polio, hepatitis B, and MMR (measles, mumps, and rubella) depending on the availability of sera.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT Concentrations for Routine Vaccines (Hib, Diphtheria, Tetanus, Hepatitis B) When Given Concomitantly With Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines for Hib, Diphtheria, Tetanus, Hepatitis B</measure>
    <time_frame>Baseline and 1 month after the 2 or 3 dose primary vaccination series</time_frame>
    <description>To assess the Enzyme-linked immunosorbent assay (ELISA) GMT of Hib, Diphtheria, Tetanus, Hepatitis B, administered Concomitantly with Novartis MenACWY Ad+ or MenACWY Ad-conjugate vaccines, at the baseline and 1 month after primary vaccination by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroup C Following 2 Doses of MenACWY Ad+ or Ad- Conjugate Vaccine (Containing 5 μg of MenC Oligosaccharide) or 2 Doses of Menjugate (Containing 10 μg of MenC Oligosaccharide)</measure>
    <time_frame>Baseline and 1 month after second vaccination</time_frame>
    <description>The immunogenicity was measured as percentages of subjects with hSBA ≥ 1:4 and ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroup C, at baseline and 1 month after second vaccination by groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After 2 or 3 Dose Primary Vaccination Series With MenACWY Ad+ or MenACWY Ad-</measure>
    <time_frame>7 days after each vaccination</time_frame>
    <description>Safety and tolerability of Novartis MenACWY Ad+ and MenACWY Ad- conjugate vaccine when given in a 2 or 3 dose primary vaccination series concomitantly with licensed pediatric vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After MenACWY Ad+ and MenACWY Ad- Booster or Polysaccharide Challenge Administered at 12 Months of Age</measure>
    <time_frame>7 days after vaccination at 12 months of age</time_frame>
    <description>The safety profile of Novartis MenACWY Ad+ and MenACWY Ad- conjugate vaccines when given at 12 months of age.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">601</enrollment>
  <condition>Prevention of Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age in the UK group. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UK24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UKMenC (Menjugate at 2, 4 m)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age of the Canadian group (Prevnar at 6 months was optional and was given if available).One subgroup of subjects was given a reduced dose (1/5) of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose (1/5) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UK24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)</intervention_name>
    <description>MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.</description>
    <arm_group_label>UK24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
    <arm_group_label>CA24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)</intervention_name>
    <description>MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.</description>
    <arm_group_label>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</arm_group_label>
    <arm_group_label>UK24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
    <arm_group_label>UKMenC (Menjugate at 2, 4 m)</arm_group_label>
    <arm_group_label>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</arm_group_label>
    <arm_group_label>CA24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY PS (MenACWY-CRM, polysaccharide vaccine)</intervention_name>
    <description>MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.</description>
    <arm_group_label>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</arm_group_label>
    <arm_group_label>CA24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
    <arm_group_label>CA24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV (Hepatitis B vaccine)</intervention_name>
    <description>Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.</description>
    <arm_group_label>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</arm_group_label>
    <arm_group_label>CA24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
    <arm_group_label>CA24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F &amp; 6B conjugated to the CRM197)</intervention_name>
    <description>Prevnar was administered IM in the anterolateral area of the left thigh.</description>
    <arm_group_label>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</arm_group_label>
    <arm_group_label>CA24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
    <arm_group_label>CA24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMR (Measles, Mumps and Rubella vaccine)</intervention_name>
    <description>MMR at 12 month of age, administered in the left arm.</description>
    <arm_group_label>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</arm_group_label>
    <arm_group_label>CA24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)</intervention_name>
    <description>DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.</description>
    <arm_group_label>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</arm_group_label>
    <arm_group_label>UK24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
    <arm_group_label>UKMenC (Menjugate at 2, 4 m)</arm_group_label>
    <arm_group_label>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</arm_group_label>
    <arm_group_label>CA24+ (MenACWY Ad+ at 2, 4 m)</arm_group_label>
    <arm_group_label>UK24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
    <arm_group_label>CA24- (MenACWY Ad- at 2, 4 m)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menjugate (Men C conjugated vaccine)</intervention_name>
    <description>Menjugate was injected IM in the anterolateral area of the right thigh.</description>
    <arm_group_label>UKMenC (Menjugate at 2, 4 m)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Individuals eligible for enrollment in this study were male, and female infants:

          -  Who were healthy 2-month old infants (55-89 days, inclusive) born after full term
             pregnancy with an estimated gestational age ≥ 37 weeks, and a birth weight ≥ 2.5 kg;

          -  For whom a parent/legal guardian has given written informed consent after the nature
             of the study has been explained;

          -  Who were available for all the visits scheduled in the study;

          -  Who were in good health as determined by:

               -  Medical history;

               -  Physical examination;

               -  Clinical judgment of the investigator.

        Exclusion Criteria

        Ineligible for the study were infants:

          -  Whose parents/legal guardians were unwilling, or unable to give written informed
             consent for the subject to participate in the study;

          -  Who previously received any meningococcal vaccine;

          -  Who received prior vaccination with D, T, P (acellular, or whole cell), IPV, or OPV,
             HBV, H influenzae type b (Hib), or Pneumococcus;

          -  Who had a previously ascertained or suspected disease caused by N meningitidis, C
             diphtheriae, C tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus, or B pertussis
             (history of laboratory-confirmed or clinical condition of spasmodic cough for a period
             ≥ 2 weeks associated with apnea or whooping cough);

          -  Who had household contact with and/or intimate exposure to an individual with
             laboratory-confirmed N meningitis (serogroups A, C, W-135, or Y), B pertussis, Hib, C
             diphtheriae, Polio, or pneumococcal infection since birth;

          -  Who had a history of any anaphylactic shock, asthma, urticaria, or other allergic
             reaction after previous vaccinations, or known hypersensitivity to any vaccine
             component;

          -  Who had experienced significant acute or chronic infection within the previous 7 days,
             or fever (≥ 38.0°C) within the previous 3 days;

          -  Who had any present, or suspected serious, acute (e.g., leukemia, lymphomas), or
             chronic disease (e.g., with signs of cardiac, renal failure, or severe malnutrition,
             or insulin-dependent diabetes); or progressive neurological disease; or a genetic
             anomaly or known cytogenic disorders (e.g., Downs syndrome);

          -  Who had a known or suspected autoimmune disease or impairment /alteration of immune
             function resulting from (for example):

               -  receipt of any immunosuppressive therapy since birth;

               -  receipt of immunostimulant since birth;

               -  receipt of any systemic corticosteroid since birth.

          -  Who had a suspected or known HIV infection, or HIV-related disease;

          -  Who had ever received blood, blood products and/or plasma derivatives, or any
             parenteral immunoglobulin preparation;

          -  Who had a known bleeding diathesis, or any condition that may be associated with a
             prolonged bleeding time;

          -  Who had a history of seizure disorder:

               -  Febrile seizure;

               -  Any other seizure disorder.

          -  Who had taken systemic antibiotics (either oral or parenteral) within the previous 14
             days (EXCEPTION: subjects who received an oral or parenteral β-lactam antibiotic
             [examples: penicillin, amoxicillin, ceftriaxone, cefuroxime, cephalexin, etc.] may be
             enrolled 7 days following the last dose);

          -  Who with their parents/legal guardians were planning to leave the area of the study
             site before the end of the study period;

          -  Who had any condition that, in the opinion of the investigator, might interfere with
             the evaluation of the study objectives;

          -  Who had taken any antipyretic medication in the previous 6 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Vaccines &amp; Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vaccine Evaluation Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Research Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Vaccine Group</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008 Jan 9;299(2):173-84. doi: 10.1001/jama.2007.29-c. Erratum in: JAMA. 2011 Mar 16;305(11):1096.</citation>
    <PMID>18182599</PMID>
  </results_reference>
  <results_reference>
    <citation>Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.</citation>
    <PMID>19209097</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2005</study_first_submitted>
  <study_first_submitted_qc>December 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <results_first_submitted>September 2, 2013</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2014</results_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at two centers in Canada and one in UK.</recruitment_details>
      <pre_assignment_details>The two selected countries provided data on different infant vaccination schedules (at 2 and 4 months of age; at 2, 3, and 4 months of age: and at 2, 4, and 6 months of age), and on different recommended concomitant vaccinations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>UK234+ (MenACWY Ad+ at 2,3,4 m)</title>
          <description>Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
        </group>
        <group group_id="P2">
          <title>UK24+ (MenACWY Ad+ at 2,4 m)</title>
          <description>Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
        </group>
        <group group_id="P3">
          <title>UKMenC (Menjugate at 2,4m)</title>
          <description>Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
        </group>
        <group group_id="P4">
          <title>CA246+ (MenACWY Ad+ at 2,4,6m)</title>
          <description>Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
        <group group_id="P5">
          <title>CA24+ (MenACWY Ad+ at 2,4m)</title>
          <description>Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
        <group group_id="P6">
          <title>UK24- (MenACWY Ad- at 2,4m)</title>
          <description>Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
        </group>
        <group group_id="P7">
          <title>CA24- (MenACWY Ad- at 2,4m)</title>
          <description>Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="98"/>
                <participants group_id="P6" count="90"/>
                <participants group_id="P7" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="93"/>
                <participants group_id="P5" count="91"/>
                <participants group_id="P6" count="83"/>
                <participants group_id="P7" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inapropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>UK234+ (MenACWY Ad+ at 2,3,4 m)</title>
          <description>Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
        </group>
        <group group_id="B2">
          <title>UK24+ (MenACWY Ad+ at 2,4 m)</title>
          <description>Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
        </group>
        <group group_id="B3">
          <title>UKMenC (Menjugate at 2,4m)</title>
          <description>Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
        </group>
        <group group_id="B4">
          <title>CA246+ (MenACWY Ad+ at 2,4,6m)</title>
          <description>Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
        <group group_id="B5">
          <title>CA24+ (MenACWY Ad+ at 2,4m)</title>
          <description>Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
        <group group_id="B6">
          <title>UK24- (MenACWY Ad- at 2,4m)</title>
          <description>Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
        </group>
        <group group_id="B7">
          <title>CA24- (MenACWY Ad- at 2,4m)</title>
          <description>Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="98"/>
            <count group_id="B5" value="98"/>
            <count group_id="B6" value="90"/>
            <count group_id="B7" value="90"/>
            <count group_id="B8" value="601"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="5.4"/>
                    <measurement group_id="B2" value="61.3" spread="5.0"/>
                    <measurement group_id="B3" value="62.6" spread="6.5"/>
                    <measurement group_id="B4" value="65.6" spread="6.9"/>
                    <measurement group_id="B5" value="65.8" spread="6.9"/>
                    <measurement group_id="B6" value="64.1" spread="5.5"/>
                    <measurement group_id="B7" value="69.4" spread="10.0"/>
                    <measurement group_id="B8" value="64.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="44"/>
                    <measurement group_id="B8" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="46"/>
                    <measurement group_id="B8" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Vaccine</title>
        <description>Immunogenicity was measured as the percentage of subjects with human serum bactericidal assay (hSBA) titers ≥ 1:4 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W and Y, at the baseline and 1 month after primary vaccination by groups.</description>
        <time_frame>Baseline and at 1 month after the 3 dose primary vaccination series</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Vaccine</title>
          <description>Immunogenicity was measured as the percentage of subjects with human serum bactericidal assay (hSBA) titers ≥ 1:4 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W and Y, at the baseline and 1 month after primary vaccination by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - baseline (n=69,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="14"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - 1 month after primary vacc (n=69,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="84" upper_limit="98"/>
                    <measurement group_id="O2" value="81" lower_limit="71" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - baseline (n=79,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="10" upper_limit="28"/>
                    <measurement group_id="O2" value="15" lower_limit="8" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - 1 month after primary vacc (n=79,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="89" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - baseline (n=69,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="41" upper_limit="66"/>
                    <measurement group_id="O2" value="31" lower_limit="21" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - 1 month after primary vacc (n=69,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="13" upper_limit="31"/>
                    <measurement group_id="O2" value="17" lower_limit="10" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - 1 month after primary vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="86" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:8 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Conjugate Vaccine</title>
        <description>Immunogenicity was measured by percentages of subjects With hSBA titers ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W and Y, at baseline and 1 month after primary vaccination by groups.</description>
        <time_frame>Baseline and 1 month after the 3 dose primary vaccination series</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:8 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Conjugate Vaccine</title>
          <description>Immunogenicity was measured by percentages of subjects With hSBA titers ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W and Y, at baseline and 1 month after primary vaccination by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - baseline (n=69,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - 1 month after primary vacc (n=69,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="78" upper_limit="95"/>
                    <measurement group_id="O2" value="76" lower_limit="65" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - baseline (n=79,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - 1 month after primary vacc (n=79,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="84" upper_limit="97"/>
                    <measurement group_id="O2" value="98" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - baseline (n=69,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="34" upper_limit="59"/>
                    <measurement group_id="O2" value="28" lower_limit="19" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - 1 month after primary vacc (n=69,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="78" upper_limit="95"/>
                    <measurement group_id="O2" value="96" lower_limit="89" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="7" upper_limit="23"/>
                    <measurement group_id="O2" value="11" lower_limit="6" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - 1 month after primary vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="85" upper_limit="97"/>
                    <measurement group_id="O2" value="89" lower_limit="80" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers (GMTs) Following 3 Doses of MenACWY Ad+ Conjugate Vaccine</title>
        <description>Immunogenicity was measured as hSBA GMTs and associated 95% CI, against N meningitis serogroups A, C, W, and Y, at the baseline and 1 month after primary vaccination by groups.</description>
        <time_frame>Baseline and 1 month after the 3 dose primary vaccination series</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMTs) Following 3 Doses of MenACWY Ad+ Conjugate Vaccine</title>
          <description>Immunogenicity was measured as hSBA GMTs and associated 95% CI, against N meningitis serogroups A, C, W, and Y, at the baseline and 1 month after primary vaccination by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - baseline (n=69,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="2.04" upper_limit="2.38"/>
                    <measurement group_id="O2" value="2" lower_limit="1.86" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - 1 month after primary vacc (n=69,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="38" upper_limit="74"/>
                    <measurement group_id="O2" value="21" lower_limit="15" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - baseline (n=79,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="2.36" upper_limit="3.31"/>
                    <measurement group_id="O2" value="2.64" lower_limit="2.25" upper_limit="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - 1 month after primary vacc (n=79,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="56" upper_limit="112"/>
                    <measurement group_id="O2" value="124" lower_limit="89" upper_limit="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - baseline (n=69,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.76" lower_limit="4.39" upper_limit="7.57"/>
                    <measurement group_id="O2" value="4.03" lower_limit="3.12" upper_limit="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - 1 month after primary vacc (n=69,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="46" upper_limit="92"/>
                    <measurement group_id="O2" value="73" lower_limit="53" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" lower_limit="2.34" upper_limit="3.17"/>
                    <measurement group_id="O2" value="2.64" lower_limit="2.28" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - 1 month after primary vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="41" upper_limit="77"/>
                    <measurement group_id="O2" value="2.64" lower_limit="2.28" upper_limit="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 Against N. Meningitidis Serogroups A, C, W, and Y Following 2 Doses of Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines</title>
        <description>Immunogenicity was measured as the percentages of subjects With hSBA titers ≥ 1:4 and ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, at Baseline and 1 month after second vaccination by groups.</description>
        <time_frame>Baseline and 1 month after second vaccination</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population.</population>
        <group_list>
          <group group_id="O1">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose (one fifth) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age. One dose of MenACWY Ad- vaccine or one reduced dose (one fifth) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 Against N. Meningitidis Serogroups A, C, W, and Y Following 2 Doses of Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines</title>
          <description>Immunogenicity was measured as the percentages of subjects With hSBA titers ≥ 1:4 and ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, at Baseline and 1 month after second vaccination by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - hSBA ≥1:4, baseline (N=68,79,78,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O4" value="4" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:4, 1m after 2n vacc(N=68,79,78,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="48" upper_limit="72"/>
                    <measurement group_id="O2" value="66" lower_limit="54" upper_limit="76"/>
                    <measurement group_id="O3" value="50" lower_limit="38" upper_limit="62"/>
                    <measurement group_id="O4" value="57" lower_limit="45" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, baseline (N=68,79,78,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="1" lower_limit="0.032" upper_limit="7"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O4" value="1" lower_limit="0.03" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA≥1:8, 1m after 2nd vacc(N=68,79,78,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="42" upper_limit="67"/>
                    <measurement group_id="O2" value="58" lower_limit="47" upper_limit="69"/>
                    <measurement group_id="O3" value="44" lower_limit="32" upper_limit="55"/>
                    <measurement group_id="O4" value="49" lower_limit="38" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4, baseline (N=77,74,79,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="6" upper_limit="23"/>
                    <measurement group_id="O2" value="15" lower_limit="8" upper_limit="25"/>
                    <measurement group_id="O3" value="20" lower_limit="12" upper_limit="31"/>
                    <measurement group_id="O4" value="20" lower_limit="12" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4,1m after 2nd vacc(N=77,74,79,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O2" value="91" lower_limit="81" upper_limit="96"/>
                    <measurement group_id="O3" value="86" lower_limit="76" upper_limit="93"/>
                    <measurement group_id="O4" value="93" lower_limit="85" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8, baseline (N=77,74,79,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O2" value="15" lower_limit="8" upper_limit="25"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O4" value="11" lower_limit="5" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8,1m after 2nd vacc(N=77,74,79,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="73" upper_limit="91"/>
                    <measurement group_id="O2" value="85" lower_limit="75" upper_limit="92"/>
                    <measurement group_id="O3" value="82" lower_limit="72" upper_limit="90"/>
                    <measurement group_id="O4" value="89" lower_limit="81" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4, baseline (N=73,74,72,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="34" upper_limit="57"/>
                    <measurement group_id="O2" value="24" lower_limit="15" upper_limit="36"/>
                    <measurement group_id="O3" value="43" lower_limit="31" upper_limit="55"/>
                    <measurement group_id="O4" value="19" lower_limit="11" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4,1m after 2nd vacc(N=73,74,72,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="83" upper_limit="97"/>
                    <measurement group_id="O2" value="91" lower_limit="81" upper_limit="96"/>
                    <measurement group_id="O3" value="82" lower_limit="71" upper_limit="90"/>
                    <measurement group_id="O4" value="95" lower_limit="87" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8, baseline (N=73,74,72,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="26" upper_limit="49"/>
                    <measurement group_id="O2" value="19" lower_limit="11" upper_limit="30"/>
                    <measurement group_id="O3" value="36" lower_limit="25" upper_limit="48"/>
                    <measurement group_id="O4" value="16" lower_limit="9" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W -hSBA ≥1:8,1m after 2nd vacc(N=73,74,72,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="73" upper_limit="91"/>
                    <measurement group_id="O2" value="85" lower_limit="75" upper_limit="92"/>
                    <measurement group_id="O3" value="75" lower_limit="63" upper_limit="84"/>
                    <measurement group_id="O4" value="92" lower_limit="83" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4, baseline (N=76,74,77,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="10" upper_limit="29"/>
                    <measurement group_id="O2" value="9" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O3" value="35" lower_limit="25" upper_limit="47"/>
                    <measurement group_id="O4" value="18" lower_limit="10" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y -hSBA ≥1:4,1m after 2nd vacc(N=76,74,77,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O2" value="86" lower_limit="77" upper_limit="93"/>
                    <measurement group_id="O3" value="74" lower_limit="63" upper_limit="83"/>
                    <measurement group_id="O4" value="91" lower_limit="82" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, baseline (N=76,74,77,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O3" value="16" lower_limit="8" upper_limit="26"/>
                    <measurement group_id="O4" value="11" lower_limit="5" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y -hSBA ≥1:8,1m after 2nd vacc(N=76,74,77,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="65" upper_limit="85"/>
                    <measurement group_id="O2" value="80" lower_limit="69" upper_limit="88"/>
                    <measurement group_id="O3" value="70" lower_limit="59" upper_limit="80"/>
                    <measurement group_id="O4" value="86" lower_limit="77" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titer (GMTs) Following 2 Doses of MenACWY Ad+ and MenACWY Ad- Conjugate Vaccines</title>
        <description>Immunogenicity was measured as hSBA GMTs and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y at baseline and 1 month after second vaccination by groups.</description>
        <time_frame>Baseline and 1 month after second vaccination</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population</population>
        <group_list>
          <group group_id="O1">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age. One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titer (GMTs) Following 2 Doses of MenACWY Ad+ and MenACWY Ad- Conjugate Vaccines</title>
          <description>Immunogenicity was measured as hSBA GMTs and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y at baseline and 1 month after second vaccination by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - baseline (n=68,79,78,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="2.01" upper_limit="2.35"/>
                    <measurement group_id="O2" value="2.07" lower_limit="1.93" upper_limit="2.23"/>
                    <measurement group_id="O3" value="2.05" lower_limit="1.91" upper_limit="2.21"/>
                    <measurement group_id="O4" value="2.08" lower_limit="1.94" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - 1 month after 2nd vacc (n=68,79,78,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="8.36" upper_limit="16"/>
                    <measurement group_id="O2" value="11" lower_limit="7.91" upper_limit="15"/>
                    <measurement group_id="O3" value="7.3" lower_limit="5.31" upper_limit="10"/>
                    <measurement group_id="O4" value="7.16" lower_limit="5.26" upper_limit="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - baseline (n=77,74,79,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" lower_limit="2.14" upper_limit="3.02"/>
                    <measurement group_id="O2" value="2.77" lower_limit="2.33" upper_limit="3.31"/>
                    <measurement group_id="O3" value="2.48" lower_limit="2.09" upper_limit="2.94"/>
                    <measurement group_id="O4" value="2.87" lower_limit="2.44" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - 1 month after 2nd vacc (n=77,74,79,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="37" upper_limit="74"/>
                    <measurement group_id="O2" value="55" lower_limit="38" upper_limit="79"/>
                    <measurement group_id="O3" value="40" lower_limit="28" upper_limit="57"/>
                    <measurement group_id="O4" value="69" lower_limit="49" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - baseline (n=73,74,79,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" lower_limit="4.09" upper_limit="6.94"/>
                    <measurement group_id="O2" value="3.6" lower_limit="2.77" upper_limit="4.69"/>
                    <measurement group_id="O3" value="5.14" lower_limit="3.94" upper_limit="6.71"/>
                    <measurement group_id="O4" value="3.02" lower_limit="2.33" upper_limit="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - 1 month after 2nd vacc (n=73,74,79,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="34" upper_limit="67"/>
                    <measurement group_id="O2" value="44" lower_limit="31" upper_limit="61"/>
                    <measurement group_id="O3" value="29" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O4" value="69" lower_limit="50" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - baseline (n=76,74,77,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" lower_limit="2.19" upper_limit="2.99"/>
                    <measurement group_id="O2" value="2.27" lower_limit="1.94" upper_limit="2.66"/>
                    <measurement group_id="O3" value="3.39" lower_limit="2.9" upper_limit="3.96"/>
                    <measurement group_id="O4" value="2.76" lower_limit="2.38" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - 1 month after 2nd vacc (n=76,74,77,85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="19" upper_limit="37"/>
                    <measurement group_id="O2" value="27" lower_limit="19" upper_limit="38"/>
                    <measurement group_id="O3" value="21" lower_limit="15" upper_limit="29"/>
                    <measurement group_id="O4" value="41" lower_limit="30" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 Against N. Meningitidis Serogroups A, C, W &amp; Y After a Booster Dose of MenACWY Ad+ or Ad- Vaccine in a Subgroup of Subjects Following 2 or 3 Doses or MenACWY Ad+ or 2 Doses of MenACWY Ad- Vaccine</title>
        <description>Immunogenicity was measured as the percentages of subjects with hSBA ≥ 1:4 or ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after booster by groups.</description>
        <time_frame>at 12 months of age and 1 month after booster vaccination</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age. One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 Against N. Meningitidis Serogroups A, C, W &amp; Y After a Booster Dose of MenACWY Ad+ or Ad- Vaccine in a Subgroup of Subjects Following 2 or 3 Doses or MenACWY Ad+ or 2 Doses of MenACWY Ad- Vaccine</title>
          <description>Immunogenicity was measured as the percentages of subjects with hSBA ≥ 1:4 or ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after booster by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A -hSBA ≥1:4, at 12 m of age(n=64,61,62,39,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="17"/>
                    <measurement group_id="O2" value="7" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="O3" value="21" lower_limit="12" upper_limit="33"/>
                    <measurement group_id="O4" value="5" lower_limit="1" upper_limit="17"/>
                    <measurement group_id="O5" value="3" lower_limit="0.067" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A -hSBA≥1:4, 1 m after booster vacc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="75" upper_limit="93"/>
                    <measurement group_id="O2" value="79" lower_limit="66" upper_limit="88"/>
                    <measurement group_id="O3" value="94" lower_limit="84" upper_limit="98"/>
                    <measurement group_id="O4" value="92" lower_limit="79" upper_limit="98"/>
                    <measurement group_id="O5" value="95" lower_limit="82" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, at 12 months of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="14"/>
                    <measurement group_id="O3" value="13" lower_limit="6" upper_limit="24"/>
                    <measurement group_id="O4" value="3" lower_limit="0.065" upper_limit="13"/>
                    <measurement group_id="O5" value="3" lower_limit="0.067" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, 1 m after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="71" upper_limit="91"/>
                    <measurement group_id="O2" value="77" lower_limit="65" upper_limit="87"/>
                    <measurement group_id="O3" value="92" lower_limit="82" upper_limit="97"/>
                    <measurement group_id="O4" value="90" lower_limit="76" upper_limit="97"/>
                    <measurement group_id="O5" value="92" lower_limit="79" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C -hSBA ≥1:4, at 12 m of age(n=67,63,65,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="28" upper_limit="53"/>
                    <measurement group_id="O2" value="33" lower_limit="22" upper_limit="46"/>
                    <measurement group_id="O3" value="60" lower_limit="47" upper_limit="72"/>
                    <measurement group_id="O4" value="48" lower_limit="32" upper_limit="64"/>
                    <measurement group_id="O5" value="33" lower_limit="19" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C-hSBA≥1:4,1 m after booster(n=57,63,65,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="87" upper_limit="99"/>
                    <measurement group_id="O2" value="94" lower_limit="85" upper_limit="98"/>
                    <measurement group_id="O3" value="98" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O4" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C-hSBA ≥1:8, at 12 m of age(n=67,40,65,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="23" upper_limit="47"/>
                    <measurement group_id="O2" value="27" lower_limit="17" upper_limit="40"/>
                    <measurement group_id="O3" value="52" lower_limit="40" upper_limit="65"/>
                    <measurement group_id="O4" value="35" lower_limit="21" upper_limit="52"/>
                    <measurement group_id="O5" value="25" lower_limit="13" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C-hSBA≥1:8, 1m after booster(n=67,63,65,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="87" upper_limit="99"/>
                    <measurement group_id="O2" value="94" lower_limit="85" upper_limit="98"/>
                    <measurement group_id="O3" value="98" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O4" value="95" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W -hSBA≥1:4, at 12 m of age(n=57,41,57,35,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="42" upper_limit="69"/>
                    <measurement group_id="O2" value="54" lower_limit="37" upper_limit="69"/>
                    <measurement group_id="O3" value="81" lower_limit="68" upper_limit="90"/>
                    <measurement group_id="O4" value="74" lower_limit="57" upper_limit="88"/>
                    <measurement group_id="O5" value="69" lower_limit="51" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA≥1:4, 1m after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W -hSBA≥1:8, at 12 m of age(n=57,41,40,35,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="34" upper_limit="61"/>
                    <measurement group_id="O2" value="41" lower_limit="26" upper_limit="58"/>
                    <measurement group_id="O3" value="68" lower_limit="55" upper_limit="80"/>
                    <measurement group_id="O4" value="49" lower_limit="31" upper_limit="66"/>
                    <measurement group_id="O5" value="54" lower_limit="37" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W -hSBA≥1:8,1m after booster(n=57,41,57,35,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y -hSBA≥1:4, at 12m of age(n=66,63,65,40,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="39" upper_limit="64"/>
                    <measurement group_id="O2" value="52" lower_limit="39" upper_limit="65"/>
                    <measurement group_id="O3" value="86" lower_limit="75" upper_limit="93"/>
                    <measurement group_id="O4" value="65" lower_limit="48" upper_limit="79"/>
                    <measurement group_id="O5" value="63" lower_limit="46" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA≥1:4, 1 m after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, at 12 months of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="28" upper_limit="52"/>
                    <measurement group_id="O2" value="41" lower_limit="29" upper_limit="54"/>
                    <measurement group_id="O3" value="72" lower_limit="60" upper_limit="83"/>
                    <measurement group_id="O4" value="45" lower_limit="29" upper_limit="62"/>
                    <measurement group_id="O5" value="53" lower_limit="36" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, 1 m after booster vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers (GMT) After a Booster Dose of MenACWY Ad+ or Ad- Vaccine Conjugate in a Subgroup of Subjects Following Either 2 or 3 Doses of MenACWY Ad+ Vaccine or 2 Doses of MenACWY Ad- Conjugate Vaccines</title>
        <description>Immunogenicity was measured as GMT and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after booster by group.</description>
        <time_frame>at 12 months of age and 1 month after booster vaccination</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA24+ (MenACWY Ad+ at 2, 4m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMT) After a Booster Dose of MenACWY Ad+ or Ad- Vaccine Conjugate in a Subgroup of Subjects Following Either 2 or 3 Doses of MenACWY Ad+ Vaccine or 2 Doses of MenACWY Ad- Conjugate Vaccines</title>
          <description>Immunogenicity was measured as GMT and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after booster by group.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - at 12 months of age (n=64,61,62,39,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="2" upper_limit="2.66"/>
                    <measurement group_id="O2" value="2.22" lower_limit="1.92" upper_limit="2.57"/>
                    <measurement group_id="O3" value="2.97" lower_limit="2.57" upper_limit="3.44"/>
                    <measurement group_id="O4" value="2.18" lower_limit="1.74" upper_limit="2.73"/>
                    <measurement group_id="O5" value="2.07" lower_limit="1.65" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - 1 month after booster (n=64,61,62,39,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="31" upper_limit="72"/>
                    <measurement group_id="O2" value="30" lower_limit="19" upper_limit="47"/>
                    <measurement group_id="O3" value="134" lower_limit="87" upper_limit="207"/>
                    <measurement group_id="O4" value="67" lower_limit="43" upper_limit="106"/>
                    <measurement group_id="O5" value="59" lower_limit="38" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - at 12 months of age(n=67,63,65,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" lower_limit="3.83" upper_limit="7.02"/>
                    <measurement group_id="O2" value="3.94" lower_limit="2.88" upper_limit="5.39"/>
                    <measurement group_id="O3" value="7.94" lower_limit="5.84" upper_limit="11"/>
                    <measurement group_id="O4" value="4.64" lower_limit="3.11" upper_limit="6.91"/>
                    <measurement group_id="O5" value="4.07" lower_limit="2.73" upper_limit="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - 1 month after booster(n=67,63,65,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236" lower_limit="159" upper_limit="349"/>
                    <measurement group_id="O2" value="129" lower_limit="86" upper_limit="194"/>
                    <measurement group_id="O3" value="429" lower_limit="288" upper_limit="639"/>
                    <measurement group_id="O4" value="216" lower_limit="130" upper_limit="356"/>
                    <measurement group_id="O5" value="258" lower_limit="56" upper_limit="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - at 12 months of age(n=57,41,57,35,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="5.76" upper_limit="11"/>
                    <measurement group_id="O2" value="6.49" lower_limit="4.34" upper_limit="9.7"/>
                    <measurement group_id="O3" value="16" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="O4" value="8.84" lower_limit="5.63" upper_limit="14"/>
                    <measurement group_id="O5" value="11" lower_limit="7.04" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - 1 month after booster (n=57,41,57,35,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503" lower_limit="347" upper_limit="732"/>
                    <measurement group_id="O2" value="311" lower_limit="200" upper_limit="485"/>
                    <measurement group_id="O3" value="792" lower_limit="544" upper_limit="1154"/>
                    <measurement group_id="O4" value="381" lower_limit="224" upper_limit="650"/>
                    <measurement group_id="O5" value="402" lower_limit="236" upper_limit="684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - at 12 months of age (n=66,63,65,40,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" lower_limit="4.88" upper_limit="9.06"/>
                    <measurement group_id="O2" value="6.83" lower_limit="4.98" upper_limit="9.37"/>
                    <measurement group_id="O3" value="19" lower_limit="14" upper_limit="26"/>
                    <measurement group_id="O4" value="7.99" lower_limit="5.29" upper_limit="12"/>
                    <measurement group_id="O5" value="7.63" lower_limit="5" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y- 1 month after booster(n=66,63,65,40,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508" lower_limit="358" upper_limit="723"/>
                    <measurement group_id="O2" value="438" lower_limit="305" upper_limit="628"/>
                    <measurement group_id="O3" value="1395" lower_limit="979" upper_limit="1989"/>
                    <measurement group_id="O4" value="308" lower_limit="191" upper_limit="499"/>
                    <measurement group_id="O5" value="527" lower_limit="322" upper_limit="862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroups A, C, W and Y Following 2 Doses of Novartis MenACWY Ad+ Vaccine, Novartis MenACWY Ad- Vaccine or Novartis Menjugate Vaccine</title>
        <description>The persistence of immune response was measured as the percentages of subjects with hSBA ≥ 1:4 and ≥ 1:8 against N. Meningitidis serogroups A, C, W, and Y at 12 months of age by groups.</description>
        <time_frame>at 12 months of age</time_frame>
        <population>The analysis was performed on the MenACWY and Menjugate per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>UKMenC (Menjugate 2, 4 m)</title>
            <description>Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose ( of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroups A, C, W and Y Following 2 Doses of Novartis MenACWY Ad+ Vaccine, Novartis MenACWY Ad- Vaccine or Novartis Menjugate Vaccine</title>
          <description>The persistence of immune response was measured as the percentages of subjects with hSBA ≥ 1:4 and ≥ 1:8 against N. Meningitidis serogroups A, C, W, and Y at 12 months of age by groups.</description>
          <population>The analysis was performed on the MenACWY and Menjugate per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - hSBA ≥1:4, at 12m of age(n=36,62,65,77,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="3" upper_limit="18"/>
                    <measurement group_id="O3" value="6" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O4" value="8" lower_limit="3" upper_limit="16"/>
                    <measurement group_id="O5" value="5" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, at 12m of age(n=36,62,65,77,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O4" value="5" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="O5" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4, at 12m of age(n=38,69,69,73,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="75" upper_limit="97"/>
                    <measurement group_id="O2" value="41" lower_limit="29" upper_limit="53"/>
                    <measurement group_id="O3" value="32" lower_limit="21" upper_limit="44"/>
                    <measurement group_id="O4" value="48" lower_limit="36" upper_limit="60"/>
                    <measurement group_id="O5" value="35" lower_limit="24" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8, at 12m of age(n=38,69,69,73,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="72" upper_limit="96"/>
                    <measurement group_id="O2" value="33" lower_limit="22" upper_limit="46"/>
                    <measurement group_id="O3" value="26" lower_limit="16" upper_limit="38"/>
                    <measurement group_id="O4" value="40" lower_limit="28" upper_limit="52"/>
                    <measurement group_id="O5" value="30" lower_limit="20" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4, at 12m of age(n=34,62,42,69,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="2" upper_limit="24"/>
                    <measurement group_id="O2" value="58" lower_limit="45" upper_limit="70"/>
                    <measurement group_id="O3" value="57" lower_limit="41" upper_limit="72"/>
                    <measurement group_id="O4" value="64" lower_limit="51" upper_limit="75"/>
                    <measurement group_id="O5" value="75" lower_limit="64" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8, at 12m of age(n=34,62,42,69,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="1" upper_limit="20"/>
                    <measurement group_id="O2" value="48" lower_limit="35" upper_limit="61"/>
                    <measurement group_id="O3" value="45" lower_limit="30" upper_limit="61"/>
                    <measurement group_id="O4" value="52" lower_limit="40" upper_limit="64"/>
                    <measurement group_id="O5" value="61" lower_limit="48" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4, at 12m of age(n=38,69,66,73,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="18"/>
                    <measurement group_id="O2" value="51" lower_limit="38" upper_limit="63"/>
                    <measurement group_id="O3" value="56" lower_limit="43" upper_limit="68"/>
                    <measurement group_id="O4" value="60" lower_limit="48" upper_limit="72"/>
                    <measurement group_id="O5" value="59" lower_limit="48" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, at 12m of age(n=38,69,66,73,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.067" upper_limit="14"/>
                    <measurement group_id="O2" value="42" lower_limit="30" upper_limit="55"/>
                    <measurement group_id="O3" value="45" lower_limit="33" upper_limit="58"/>
                    <measurement group_id="O4" value="51" lower_limit="39" upper_limit="63"/>
                    <measurement group_id="O5" value="46" lower_limit="34" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers (GMTs) After 2 Doses of Novartis MenACWY Ad+ Vaccines, Novartis MenACWY Ad- Vaccine, or Novartis Menjugate Vaccine.</title>
        <description>The persistence of immune response as measured by hSBA GMT and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age by groups.</description>
        <time_frame>at 12 months of age</time_frame>
        <population>The analysis was performed on the MenACWY and Menjugate per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>UKMenC (Menjugate at 2, 4 m)</title>
            <description>Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMTs) After 2 Doses of Novartis MenACWY Ad+ Vaccines, Novartis MenACWY Ad- Vaccine, or Novartis Menjugate Vaccine.</title>
          <description>The persistence of immune response as measured by hSBA GMT and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age by groups.</description>
          <population>The analysis was performed on the MenACWY and Menjugate per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - at 12 months of age (n=36,62,65,77,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.62" upper_limit="2.48"/>
                    <measurement group_id="O2" value="2.32" lower_limit="1.97" upper_limit="2.73"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.88" upper_limit="2.58"/>
                    <measurement group_id="O4" value="2.29" lower_limit="1.98" upper_limit="2.65"/>
                    <measurement group_id="O5" value="2.18" lower_limit="1.89" upper_limit="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - at 12 months of age (n=36,69,69,73,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="O2" value="5.04" lower_limit="3.73" upper_limit="6.81"/>
                    <measurement group_id="O3" value="3.85" lower_limit="2.85" upper_limit="5.21"/>
                    <measurement group_id="O4" value="5.43" lower_limit="4.05" upper_limit="7.27"/>
                    <measurement group_id="O5" value="4.42" lower_limit="3.35" upper_limit="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - at 12 months of age (n=34,62,42,69,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="1.55" upper_limit="3.78"/>
                    <measurement group_id="O2" value="8.38" lower_limit="6.03" upper_limit="12"/>
                    <measurement group_id="O3" value="7.02" lower_limit="4.71" upper_limit="10"/>
                    <measurement group_id="O4" value="8.15" lower_limit="5.97" upper_limit="11"/>
                    <measurement group_id="O5" value="12" lower_limit="8.81" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - at 12 months of age (n=38,69,66,73,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="1.41" upper_limit="3.28"/>
                    <measurement group_id="O2" value="6.72" lower_limit="4.92" upper_limit="9.18"/>
                    <measurement group_id="O3" value="7.64" lower_limit="5.55" upper_limit="11"/>
                    <measurement group_id="O4" value="7.84" lower_limit="5.79" upper_limit="11"/>
                    <measurement group_id="O5" value="7.12" lower_limit="5.32" upper_limit="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroup A, C, W and Y Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</title>
        <description>The persistence of immune response as measured by percentages of subjects with hSBA≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y, at 12 months by groups.</description>
        <time_frame>at 12 months of age</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age</description>
          </group>
          <group group_id="O2">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroup A, C, W and Y Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</title>
          <description>The persistence of immune response as measured by percentages of subjects with hSBA≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y, at 12 months by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - hSBA ≥1:4, at 12 months of age (n=58,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="11" upper_limit="33"/>
                    <measurement group_id="O2" value="35" lower_limit="25" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, at 12 months of age(n=58,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="7" upper_limit="27"/>
                    <measurement group_id="O2" value="29" lower_limit="19" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4, at 12 months of age(n=70,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="46" upper_limit="70"/>
                    <measurement group_id="O2" value="75" lower_limit="64" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8, at 12 months of age(n=70,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="35" upper_limit="59"/>
                    <measurement group_id="O2" value="68" lower_limit="57" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4, at 12 months of age(n=58,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="65" upper_limit="87"/>
                    <measurement group_id="O2" value="89" lower_limit="80" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8, at 12 months of age(n=58,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="52" upper_limit="78"/>
                    <measurement group_id="O2" value="81" lower_limit="71" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4, at 12 months of age(n=71,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O2" value="87" lower_limit="78" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, at 12 months of age(n=71,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="58" upper_limit="81"/>
                    <measurement group_id="O2" value="79" lower_limit="69" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers (GMTs) Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</title>
        <description>The persistence of immune response as measured by hSBA GMTs and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y,at 12 months by groups.</description>
        <time_frame>at 12 months of age</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMTs) Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</title>
          <description>The persistence of immune response as measured by hSBA GMTs and associated 95% CI against N. Meningitidis serogroups A, C, W, and Y,at 12 months by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - at 12 months of age (n=58,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="2.55" upper_limit="3.57"/>
                    <measurement group_id="O2" value="3.93" lower_limit="3.4" upper_limit="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - at 12 months of age (n=70,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.56" lower_limit="5.61" upper_limit="10"/>
                    <measurement group_id="O2" value="14" lower_limit="10" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - at 12 months of age (n=58,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="10" upper_limit="21"/>
                    <measurement group_id="O2" value="20" lower_limit="15" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - at 12 months of age (n=71,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O2" value="22" lower_limit="17" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</title>
        <description>The induction of immunological memory was measured as percentages of subjects with hSBA ≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y , before challenge at 12 months of age and 1 month after PS challenge.</description>
        <time_frame>before challenge at 12 months of age and 1 month after PS challenge.</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>CA246+ (MenACWY Ad+ at 2,4,6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</title>
          <description>The induction of immunological memory was measured as percentages of subjects with hSBA ≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, against N. Meningitidis serogroups A, C, W, and Y , before challenge at 12 months of age and 1 month after PS challenge.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A-hSBA≥1:4,before challenge at 12m (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="15" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:4, 1 month after PS (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="75" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A-hSBA ≥1:8,before challenge at 12m (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="11" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, 1 month after PS (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="73" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C-hSBA ≥1:4,before challenge at 12m (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="59" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4, 1 month after PS (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="84" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C-hSBA ≥1:8, before challenge at 12m (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="49" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8, 1 month after PS (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="78" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W-hSBA ≥1:4,before challenge at 12m (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="67" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4, 1 month after PS (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W-hSBA ≥1:8,before challenge at 12m (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="56" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8, 1 month after PS (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y-hSBA ≥1:4,before challenge at 12m (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="75" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4, 1 month after PS (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="88" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y-hSBA ≥1:8,before challenge at 12m (N=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="62" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, 1 month after PS (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="88" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers (GMTs) in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</title>
        <description>The induction of immunological memory was measured as hSBA Geometric Mean Titers (GMTs) and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y , before challenge at 12 months of age and 1 month after PS challenge.</description>
        <time_frame>before challenge at 12 months of age and 1 month after PS challenge.</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>CA246+ (MenACWY Ad+ at 2, 4,6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMTs) in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following 3 Doses of Novartis MenACWY Ad+ Conjugate Vaccine</title>
          <description>The induction of immunological memory was measured as hSBA Geometric Mean Titers (GMTs) and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y , before challenge at 12 months of age and 1 month after PS challenge.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - before challenge at 12 months of age(n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.75" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - 1 month after PS challenge (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="21" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - before challenge at 12 months of age(n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="8.41" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - 1 month after PS challenge (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="50" upper_limit="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - before challenge at 12 months of age(n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="11" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - 1 month after PS challenge (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249" lower_limit="152" upper_limit="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - before challenge at 12 months of age(n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="13" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - 1 month after PS challenge (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" lower_limit="117" upper_limit="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following Two Doses of Novartis MenACWY Ad+ or MenACWY Ad- Conjugate Vaccine</title>
        <description>The Induction of immunological memory was measured as percentage of subjects with hSBA ≥ 1:4, hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, before challenge at 12 months and 1 month after PS challenge by groups.</description>
        <time_frame>Before challenge at 12 months of age and 1 month after PS challenge.</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>CA24+ (MenACWY Ad+ at 2, 4m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA24- (MenACWY Ad- at 2, 4m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:4 or ≥ 1:8 in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following Two Doses of Novartis MenACWY Ad+ or MenACWY Ad- Conjugate Vaccine</title>
          <description>The Induction of immunological memory was measured as percentage of subjects with hSBA ≥ 1:4, hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, before challenge at 12 months and 1 month after PS challenge by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - hSBA≥1:4,before challange at 12m (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="2" upper_limit="20"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:4,1 month after PS (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="62" upper_limit="89"/>
                    <measurement group_id="O2" value="92" lower_limit="79" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA≥1:8,before challange at 12m (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="17"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, 1 month after PS (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="62" upper_limit="89"/>
                    <measurement group_id="O2" value="87" lower_limit="73" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA≥1:4,before challange at 12m (n=41,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="28" upper_limit="60"/>
                    <measurement group_id="O2" value="38" lower_limit="23" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4, 1 month after PS (n=41,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O2" value="95" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA≥1:8,before challange at 12m(n=41,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="24" upper_limit="55"/>
                    <measurement group_id="O2" value="36" lower_limit="21" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8, 1 month after PS (n=41,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O2" value="90" lower_limit="76" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4,before challange at 12m(n=41,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="42" upper_limit="74"/>
                    <measurement group_id="O2" value="71" lower_limit="54" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4, 1 month after PS (n=41,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8,before challange at 12m(n=41,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="35" upper_limit="67"/>
                    <measurement group_id="O2" value="58" lower_limit="41" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8, 1 month after PS (n=41,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4,before challange at 12m(n=42,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="39" upper_limit="70"/>
                    <measurement group_id="O2" value="55" lower_limit="38" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4, 1 month after PS (n=42,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8,before challange at 12m (n=42,38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="34" upper_limit="66"/>
                    <measurement group_id="O2" value="42" lower_limit="26" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, 1 month after PS (n=42,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="97" lower_limit="86" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers (GMTs) in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following Two Doses of Novartis MenACWY Ad+ or MenACWY Ad- Conjugate Vaccine</title>
        <description>Induction of immunological memory was measured by hSBA Geometric Mean Titers (GMTs) and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, before challenge at 12 months and 1 month after PS challenge by groups.</description>
        <time_frame>Before challenge at 12 months of age and 1 month after PS challenge.</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean hSBA Titers (GMTs) in Subjects Challenged With a Reduced Dose of Licensed Meningococcal ACWY PS Vaccine Following Two Doses of Novartis MenACWY Ad+ or MenACWY Ad- Conjugate Vaccine</title>
          <description>Induction of immunological memory was measured by hSBA Geometric Mean Titers (GMTs) and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, before challenge at 12 months and 1 month after PS challenge by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - before challenge at 12 months (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" lower_limit="1.77" upper_limit="2.76"/>
                    <measurement group_id="O2" value="2.31" lower_limit="1.84" upper_limit="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - 1 month after PS challenge (n=40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="18" upper_limit="44"/>
                    <measurement group_id="O2" value="55" lower_limit="35" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - before challenge at 12 months (n=41,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" lower_limit="3.51" upper_limit="7.72"/>
                    <measurement group_id="O2" value="5.07" lower_limit="3.38" upper_limit="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - 1 month after PS challenge (n=41,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" lower_limit="85" upper_limit="231"/>
                    <measurement group_id="O2" value="181" lower_limit="109" upper_limit="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - before challenge at 12 months (n=41,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" lower_limit="4.94" upper_limit="11"/>
                    <measurement group_id="O2" value="11" lower_limit="7.08" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - 1 month after PS challenge (n=41,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365" lower_limit="224" upper_limit="597"/>
                    <measurement group_id="O2" value="555" lower_limit="333" upper_limit="924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - before challenge at 12 months (n=42,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" lower_limit="4.51" upper_limit="10"/>
                    <measurement group_id="O2" value="6.79" lower_limit="4.45" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - 1 month after PS challenge (n=42,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280" lower_limit="175" upper_limit="448"/>
                    <measurement group_id="O2" value="288" lower_limit="176" upper_limit="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 of MenACWY Ad+ Conjugate Vaccine</title>
        <description>The immunogenicity was measured as percentages of subject with hSBA≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, baseline and 1 month after 2 or 3 dose primary series by groups.</description>
        <time_frame>Baseline and 1 month after the 2 or 3 dose primary vaccination series</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was to be given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA24+ (MenACWY Ad+ at 2, 4m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 of MenACWY Ad+ Conjugate Vaccine</title>
          <description>The immunogenicity was measured as percentages of subject with hSBA≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, baseline and 1 month after 2 or 3 dose primary series by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - hSBA ≥1:4, baseline (n=69,80,38,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="14"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA≥1:4,1m after 1st vacc (n=69,80,38,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="84" upper_limit="98"/>
                    <measurement group_id="O2" value="81" lower_limit="71" upper_limit="89"/>
                    <measurement group_id="O3" value="60" lower_limit="48" upper_limit="72"/>
                    <measurement group_id="O4" value="66" lower_limit="54" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, baseline (n=69,80,38,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O4" value="1" lower_limit="0.032" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA≥1:8,1m after 1st vacc (n=69,80,38,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="78" upper_limit="95"/>
                    <measurement group_id="O2" value="76" lower_limit="65" upper_limit="85"/>
                    <measurement group_id="O3" value="54" lower_limit="42" upper_limit="67"/>
                    <measurement group_id="O4" value="58" lower_limit="47" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4, baseline (n=79,86,40,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="10" upper_limit="28"/>
                    <measurement group_id="O2" value="15" lower_limit="8" upper_limit="24"/>
                    <measurement group_id="O3" value="13" lower_limit="6" upper_limit="23"/>
                    <measurement group_id="O4" value="15" lower_limit="8" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA≥1:4,1m after 1st vacc (n=79,86,40,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="89" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O3" value="84" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O4" value="91" lower_limit="81" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8, baseline (n=79,86,40,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O3" value="9" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O4" value="15" lower_limit="8" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA≥1:8,1m after 1st vacc (n=79,86,40,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="84" upper_limit="97"/>
                    <measurement group_id="O2" value="98" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O3" value="83" lower_limit="73" upper_limit="91"/>
                    <measurement group_id="O4" value="85" lower_limit="75" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4, baseline (n=69,78,73,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="41" upper_limit="66"/>
                    <measurement group_id="O2" value="31" lower_limit="21" upper_limit="42"/>
                    <measurement group_id="O3" value="45" lower_limit="34" upper_limit="57"/>
                    <measurement group_id="O4" value="24" lower_limit="15" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA≥1:4,1m after 1st vacc (n=69,78,73,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O3" value="92" lower_limit="83" upper_limit="97"/>
                    <measurement group_id="O4" value="91" lower_limit="81" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8, baseline (n=69,78,73,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="34" upper_limit="59"/>
                    <measurement group_id="O2" value="28" lower_limit="19" upper_limit="40"/>
                    <measurement group_id="O3" value="37" lower_limit="26" upper_limit="49"/>
                    <measurement group_id="O4" value="19" lower_limit="11" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA≥1:8,1m after 1st vacc (n=69,78,73,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="78" upper_limit="95"/>
                    <measurement group_id="O2" value="96" lower_limit="89" upper_limit="99"/>
                    <measurement group_id="O3" value="84" lower_limit="73" upper_limit="91"/>
                    <measurement group_id="O4" value="85" lower_limit="75" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4, baseline (n=81,87,76,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="13" upper_limit="31"/>
                    <measurement group_id="O2" value="17" lower_limit="10" upper_limit="27"/>
                    <measurement group_id="O3" value="18" lower_limit="10" upper_limit="29"/>
                    <measurement group_id="O4" value="9" lower_limit="4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA≥1:4,1m after 1st vacc (n=81,87,76,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="86" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O3" value="84" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O4" value="86" lower_limit="77" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, baseline (n=81,87,76,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="7" upper_limit="23"/>
                    <measurement group_id="O2" value="11" lower_limit="6" upper_limit="20"/>
                    <measurement group_id="O3" value="7" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O4" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA≥1:8,1m after 1st vacc (n=81,87,76,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="85" upper_limit="97"/>
                    <measurement group_id="O2" value="89" lower_limit="80" upper_limit="94"/>
                    <measurement group_id="O3" value="76" lower_limit="65" upper_limit="85"/>
                    <measurement group_id="O4" value="80" lower_limit="69" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 in Subjects Challenged With a Reduced Dose of a Licensed Meningococcal ACWY PS Vaccine Following 2 or 3 Doses of MenACWY Ad+ Conjugate Vaccine</title>
        <description>The memory response was measured as percentages of subjects with hSBA ≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after PS challenge by groups.</description>
        <time_frame>at 12 months of age and 1 month after PS challenge</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
        <group_list>
          <group group_id="O1">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 in Subjects Challenged With a Reduced Dose of a Licensed Meningococcal ACWY PS Vaccine Following 2 or 3 Doses of MenACWY Ad+ Conjugate Vaccine</title>
          <description>The memory response was measured as percentages of subjects with hSBA ≥ 1:4 and hSBA ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroups A, C, W, and Y, at 12 months of age and 1 month after PS challenge by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population evaluating the persistence response.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ser A - hSBA ≥1:4, at 12 months of age (n=44,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="15" upper_limit="43"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:4, at 1 month after PS (n=44,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="75" upper_limit="96"/>
                    <measurement group_id="O2" value="78" lower_limit="62" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, at 12 months of age (n=44,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="11" upper_limit="38"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser A - hSBA ≥1:8, at 1 month after PS (n=44,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="73" upper_limit="95"/>
                    <measurement group_id="O2" value="78" lower_limit="62" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4, at 12 months of age (n=43,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="59" upper_limit="86"/>
                    <measurement group_id="O2" value="44" lower_limit="28" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:4, at 1 month after PS (n=43,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="84" upper_limit="99"/>
                    <measurement group_id="O2" value="95" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8, at 12 months of age (n=43,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="49" upper_limit="79"/>
                    <measurement group_id="O2" value="39" lower_limit="24" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser C - hSBA ≥1:8, at 1 month after PS (n=43,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="78" upper_limit="97"/>
                    <measurement group_id="O2" value="93" lower_limit="80" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4, at 12 months of age (n=40,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="67" upper_limit="93"/>
                    <measurement group_id="O2" value="59" lower_limit="42" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:4, at 1 month after PS (n=40,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8, at 12 months of age (n=40,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="56" upper_limit="85"/>
                    <measurement group_id="O2" value="51" lower_limit="35" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser W - hSBA ≥1:8, at 1 month after PS (n=40,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4, at 12 months of age (n=44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="75" upper_limit="96"/>
                    <measurement group_id="O2" value="55" lower_limit="39" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:4, at 1 month after PS (n=44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, at 12 months of age (n=44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="62" upper_limit="89"/>
                    <measurement group_id="O2" value="50" lower_limit="34" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ser Y - hSBA ≥1:8, at 1 month after PS (n=44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Antibody Response to Routine Vaccines (Hib, Diphtheria, Tetanus, Hepatitis B) When Routine Vaccines Are Given Concomitantly With Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines</title>
        <description>To assess the immunogenicity of routine vaccines when given concomitantly to Novartis MenACWY Ad+ or Novartis MenACWY Ad- conjugate vaccines. Hib, diphtheria, tetanus, pertussis will be evaluated as the first priority, followed by pneumococcus, polio, hepatitis B, and MMR (measles, mumps, and rubella) depending on the availability of sera.</description>
        <time_frame>Baseline and 1 month after the 2 or 3 dose primary vaccination series</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Antibody Response to Routine Vaccines (Hib, Diphtheria, Tetanus, Hepatitis B) When Routine Vaccines Are Given Concomitantly With Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines</title>
          <description>To assess the immunogenicity of routine vaccines when given concomitantly to Novartis MenACWY Ad+ or Novartis MenACWY Ad- conjugate vaccines. Hib, diphtheria, tetanus, pertussis will be evaluated as the first priority, followed by pneumococcus, polio, hepatitis B, and MMR (measles, mumps, and rubella) depending on the availability of sera.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="72"/>
                <count group_id="O6" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antitetanus≥0.1 IU/mL-baseline(69,71,70,67,69,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="64" upper_limit="85"/>
                    <measurement group_id="O2" value="79" lower_limit="68" upper_limit="88"/>
                    <measurement group_id="O3" value="70" lower_limit="58" upper_limit="80"/>
                    <measurement group_id="O4" value="93" lower_limit="83" upper_limit="98"/>
                    <measurement group_id="O5" value="87" lower_limit="77" upper_limit="94"/>
                    <measurement group_id="O6" value="71" lower_limit="59" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antitetanus≥0.1 IU/mL -1m post (69,71,70,67,69,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antidipht≥0.1 IU/mL-baseline(69,71,70,67,69,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="9" upper_limit="28"/>
                    <measurement group_id="O2" value="14" lower_limit="7" upper_limit="24"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O4" value="18" lower_limit="10" upper_limit="29"/>
                    <measurement group_id="O5" value="19" lower_limit="10" upper_limit="30"/>
                    <measurement group_id="O6" value="15" lower_limit="8" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antidipht≥0.1 IU/mL- 1m post (69,71,70,67,69,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="88" upper_limit="99"/>
                    <measurement group_id="O2" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O4" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O5" value="96" lower_limit="88" upper_limit="99"/>
                    <measurement group_id="O6" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antiPRPtiter≥0.15µg/mL-baseline(70,77,69,73,72,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="25" upper_limit="48"/>
                    <measurement group_id="O2" value="42" lower_limit="30" upper_limit="53"/>
                    <measurement group_id="O3" value="17" lower_limit="9" upper_limit="28"/>
                    <measurement group_id="O4" value="25" lower_limit="15" upper_limit="36"/>
                    <measurement group_id="O5" value="49" lower_limit="37" upper_limit="61"/>
                    <measurement group_id="O6" value="37" lower_limit="26" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antiPRPtiter≥0.15µg/mL-1m post (70,77,69,73,72,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="62" upper_limit="84"/>
                    <measurement group_id="O2" value="95" lower_limit="87" upper_limit="99"/>
                    <measurement group_id="O3" value="67" lower_limit="54" upper_limit="78"/>
                    <measurement group_id="O4" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O5" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O6" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antiPRPtiter≥1.0 µg/mL-baseline(70,77,69,73,72,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O2" value="17" lower_limit="9" upper_limit="27"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O4" value="7" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O5" value="17" lower_limit="9" upper_limit="27"/>
                    <measurement group_id="O6" value="11" lower_limit="5" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antiPRPtiter≥1.0 µg/mL-1m post (70,77,69,73,72,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="O2" value="86" lower_limit="76" upper_limit="93"/>
                    <measurement group_id="O3" value="35" lower_limit="24" upper_limit="47"/>
                    <measurement group_id="O4" value="82" lower_limit="71" upper_limit="90"/>
                    <measurement group_id="O5" value="82" lower_limit="71" upper_limit="90"/>
                    <measurement group_id="O6" value="86" lower_limit="76" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antiHBVtiter≥1.0 IU/mL-baseline(65,na,66,na,na,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="14" upper_limit="35"/>
                    <measurement group_id="O2" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O3" value="11" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O4" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O5" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O6" value="22" lower_limit="13" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>antiHBVtiter≥1.0 IU/mL-1m post (65,na,66,na,na,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O2" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O3" value="92" lower_limit="83" upper_limit="97"/>
                    <measurement group_id="O4" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O5" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O6" value="97" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMT Concentrations for Routine Vaccines (Hib, Diphtheria, Tetanus, Hepatitis B) When Given Concomitantly With Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines for Hib, Diphtheria, Tetanus, Hepatitis B</title>
        <description>To assess the Enzyme-linked immunosorbent assay (ELISA) GMT of Hib, Diphtheria, Tetanus, Hepatitis B, administered Concomitantly with Novartis MenACWY Ad+ or MenACWY Ad-conjugate vaccines, at the baseline and 1 month after primary vaccination by groups.</description>
        <time_frame>Baseline and 1 month after the 2 or 3 dose primary vaccination series</time_frame>
        <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMT Concentrations for Routine Vaccines (Hib, Diphtheria, Tetanus, Hepatitis B) When Given Concomitantly With Novartis MenACWY Ad+ or Novartis MenACWY Ad- Conjugate Vaccines for Hib, Diphtheria, Tetanus, Hepatitis B</title>
          <description>To assess the Enzyme-linked immunosorbent assay (ELISA) GMT of Hib, Diphtheria, Tetanus, Hepatitis B, administered Concomitantly with Novartis MenACWY Ad+ or MenACWY Ad-conjugate vaccines, at the baseline and 1 month after primary vaccination by groups.</description>
          <population>The analysis was performed on the MenACWY per-protocol (PP) &quot;n&quot; population after primary vaccination.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="72"/>
                <count group_id="O6" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tetanus - baseline (n=69,71,70,67,69,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.24" upper_limit="0.41"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.24" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.23" lower_limit="0.18" upper_limit="0.29"/>
                    <measurement group_id="O4" value="0.28" lower_limit="0.22" upper_limit="0.37"/>
                    <measurement group_id="O5" value="0.25" lower_limit="0.19" upper_limit="0.32"/>
                    <measurement group_id="O6" value="0.18" lower_limit="0.14" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus - 1 m after 1st vacc(n=69,71,70,67,69,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.57" upper_limit="0.87"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.75" upper_limit="1.13"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.14" upper_limit="1.72"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.48" upper_limit="0.73"/>
                    <measurement group_id="O5" value="0.97" lower_limit="0.79" upper_limit="1.19"/>
                    <measurement group_id="O6" value="0.68" lower_limit="0.55" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria - baseline (n=69,71,70,67,69,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.026" upper_limit="0.047"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.053"/>
                    <measurement group_id="O3" value="0.027" lower_limit="0.02" upper_limit="0.035"/>
                    <measurement group_id="O4" value="0.031" lower_limit="0.024" upper_limit="0.042"/>
                    <measurement group_id="O5" value="0.032" lower_limit="0.024" upper_limit="0.042"/>
                    <measurement group_id="O6" value="0.016" lower_limit="0.012" upper_limit="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria -1m after 1st vacc(n=69,71,70,67,69,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.81" upper_limit="1.29"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.82" upper_limit="1.28"/>
                    <measurement group_id="O3" value="1.72" lower_limit="1.38" upper_limit="2.14"/>
                    <measurement group_id="O4" value="1.06" lower_limit="0.84" upper_limit="1.32"/>
                    <measurement group_id="O5" value="0.98" lower_limit="0.78" upper_limit="1.22"/>
                    <measurement group_id="O6" value="1.49" lower_limit="1.19" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib - baseline (n=70,77,69,73,72,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.078" lower_limit="0.056" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.11" upper_limit="0.21"/>
                    <measurement group_id="O3" value="0.11" lower_limit="0.078" upper_limit="0.15"/>
                    <measurement group_id="O4" value="0.089" lower_limit="0.063" upper_limit="0.12"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.11" upper_limit="0.21"/>
                    <measurement group_id="O6" value="0.064" lower_limit="0.045" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib - 1 m after 1st vacc (n=70,77,69,73,72,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" lower_limit="3.14" upper_limit="6.83"/>
                    <measurement group_id="O2" value="4.55" lower_limit="3.08" upper_limit="6.72"/>
                    <measurement group_id="O3" value="4.53" lower_limit="3.07" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.47" lower_limit="0.32" upper_limit="0.7"/>
                    <measurement group_id="O5" value="5.67" lower_limit="3.89" upper_limit="8.28"/>
                    <measurement group_id="O6" value="0.42" lower_limit="0.28" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B - baseline (n=65,na,66,na,na,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O2" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O3" value="5.9" lower_limit="4.25" upper_limit="8.2"/>
                    <measurement group_id="O4" value="5.79" lower_limit="4.15" upper_limit="8.09"/>
                    <measurement group_id="O5" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O6" value="4.21" lower_limit="3.03" upper_limit="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B-1m after 1st vacc(n=65,na,66,na,na,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O2" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O3" value="378" lower_limit="258" upper_limit="554"/>
                    <measurement group_id="O4" value="69" lower_limit="47" upper_limit="102"/>
                    <measurement group_id="O5" value="NA">not performed due to insufficient sera</measurement>
                    <measurement group_id="O6" value="133" lower_limit="90" upper_limit="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroup C Following 2 Doses of MenACWY Ad+ or Ad- Conjugate Vaccine (Containing 5 μg of MenC Oligosaccharide) or 2 Doses of Menjugate (Containing 10 μg of MenC Oligosaccharide)</title>
        <description>The immunogenicity was measured as percentages of subjects with hSBA ≥ 1:4 and ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroup C, at baseline and 1 month after second vaccination by groups.</description>
        <time_frame>Baseline and 1 month after second vaccination</time_frame>
        <population>The analysis was performed on the MenACWY and Menjugate per-protocol (PP) &quot;n&quot; population after second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>UKMenC (Menjugate at 2, 4 m)</title>
            <description>Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA ≥ 1:4 and ≥ 1:8 Against N. Meningitidis Serogroup C Following 2 Doses of MenACWY Ad+ or Ad- Conjugate Vaccine (Containing 5 μg of MenC Oligosaccharide) or 2 Doses of Menjugate (Containing 10 μg of MenC Oligosaccharide)</title>
          <description>The immunogenicity was measured as percentages of subjects with hSBA ≥ 1:4 and ≥ 1:8 and associated 95% CI, directed against N. Meningitidis serogroup C, at baseline and 1 month after second vaccination by groups.</description>
          <population>The analysis was performed on the MenACWY and Menjugate per-protocol (PP) &quot;n&quot; population after second vaccination.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA ≥1:4, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="11" upper_limit="38"/>
                    <measurement group_id="O2" value="13" lower_limit="6" upper_limit="23"/>
                    <measurement group_id="O3" value="15" lower_limit="8" upper_limit="25"/>
                    <measurement group_id="O4" value="20" lower_limit="12" upper_limit="31"/>
                    <measurement group_id="O5" value="20" lower_limit="12" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:4, 1 month after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="84" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O3" value="91" lower_limit="81" upper_limit="96"/>
                    <measurement group_id="O4" value="86" lower_limit="76" upper_limit="93"/>
                    <measurement group_id="O5" value="93" lower_limit="85" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="3" upper_limit="24"/>
                    <measurement group_id="O2" value="9" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O3" value="15" lower_limit="8" upper_limit="25"/>
                    <measurement group_id="O4" value="5" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="O5" value="11" lower_limit="5" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8, 1 month after second vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="83" lower_limit="73" upper_limit="91"/>
                    <measurement group_id="O3" value="85" lower_limit="75" upper_limit="92"/>
                    <measurement group_id="O4" value="82" lower_limit="72" upper_limit="90"/>
                    <measurement group_id="O5" value="89" lower_limit="81" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After 2 or 3 Dose Primary Vaccination Series With MenACWY Ad+ or MenACWY Ad-</title>
        <description>Safety and tolerability of Novartis MenACWY Ad+ and MenACWY Ad- conjugate vaccine when given in a 2 or 3 dose primary vaccination series concomitantly with licensed pediatric vaccines.</description>
        <time_frame>7 days after each vaccination</time_frame>
        <population>Analysis was done on safety dataset &quot;n&quot; population - subjects who received at least one study dose and had Post baseline safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2, 3, 4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UKMenC (Menjugate at 2, 4 m)</title>
            <description>Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O7">
            <title>CA24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine without adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After 2 or 3 Dose Primary Vaccination Series With MenACWY Ad+ or MenACWY Ad-</title>
          <description>Safety and tolerability of Novartis MenACWY Ad+ and MenACWY Ad- conjugate vaccine when given in a 2 or 3 dose primary vaccination series concomitantly with licensed pediatric vaccines.</description>
          <population>Analysis was done on safety dataset &quot;n&quot; population - subjects who received at least one study dose and had Post baseline safety data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="98"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="73"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="78"/>
                    <measurement group_id="O7" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating habit Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="45"/>
                    <measurement group_id="O7" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="70"/>
                    <measurement group_id="O6" value="61"/>
                    <measurement group_id="O7" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesics/Antipyretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="36"/>
                    <measurement group_id="O7" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After MenACWY Ad+ and MenACWY Ad- Booster or Polysaccharide Challenge Administered at 12 Months of Age</title>
        <description>The safety profile of Novartis MenACWY Ad+ and MenACWY Ad- conjugate vaccines when given at 12 months of age.</description>
        <time_frame>7 days after vaccination at 12 months of age</time_frame>
        <population>Analysis was done on safety dataset &quot;n&quot; population.</population>
        <group_list>
          <group group_id="O1">
            <title>UK234+ (MenACWY Ad+ at 2,3,4 m)</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was given at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>UK24+ (MenACWY Ad+ at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>UKMenC (Menjugate at 2, 4 m)</title>
            <description>Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m) - No Treatment</title>
            <description>Three doses of MenACWY conjugate vaccine with adjuvant were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>CA246+ (MenACWY Ad+ at 2, 4, 6 m) - PS</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O6">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m) - ACWY</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O7">
            <title>CA24+ (MenACWY Ad+ at 2, 4 m) - PS</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad+ vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O8">
            <title>UK24- (MenACWY Ad- at 2, 4 m)</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.</description>
          </group>
          <group group_id="O9">
            <title>CA24- (MenACWY Ad- at 2, 4 m) - ACWY</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad- vaccine or one reduced dose (one fifth) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
          <group group_id="O10">
            <title>CA24- (MenACWY Ad- at 2, 4 m) - PS</title>
            <description>Two doses of MenACWY conjugate vaccine with adjuvant were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.
One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After MenACWY Ad+ and MenACWY Ad- Booster or Polysaccharide Challenge Administered at 12 Months of Age</title>
          <description>The safety profile of Novartis MenACWY Ad+ and MenACWY Ad- conjugate vaccines when given at 12 months of age.</description>
          <population>Analysis was done on safety dataset &quot;n&quot; population.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="90"/>
                <count group_id="O9" value="44"/>
                <count group_id="O10" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="66"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating habit change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesics/Antipyretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="17"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All solicited adverse events (AEs) were collected upto Day 7 after each vaccination. All SAEs and unsolicited AEs were collected throughout the study (22 months in total).</time_frame>
      <desc>Information on all AEs was to be collected for 7 days following each vaccination, after which information on only SAEs and AEs necessitating a physician’s visit and/or resulting in premature withdrawal of subjects from the study was collected until the next study visit and recorded by study personnel.</desc>
      <group_list>
        <group group_id="E1">
          <title>UK234+ (MenACWY Ad+ at 2,3,4 m)</title>
          <description>Three doses of MenACWY Ad+ vaccine were to be given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age. A fourth dose of MenACWY Ad+ was to be given at 12 months of age.</description>
        </group>
        <group group_id="E2">
          <title>UK24+ (MenACWY Ad+ at 2,4 m)</title>
          <description>Two doses of MenACWY Ad+ vaccine were to be given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was to be given at 12 months of age.</description>
        </group>
        <group group_id="E3">
          <title>UKMenC (Menjugate at 2,4m)</title>
          <description>Two doses of Menjugate® were to be given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was to be given at 12 months of age.</description>
        </group>
        <group group_id="E4">
          <title>CA246+ (MenACWY Ad+ at 2,4,6m)</title>
          <description>Three doses of MenACWY Ad+ vaccine were to be given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar® at 2, 4, and 6 months of age (Prevnar at 6 months was optional and was given if available). One subgroup of subjects was to be given a reduced dose of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was to be administered one dose of MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
        <group group_id="E5">
          <title>CA24+ (MenACWY Ad+ at 2,4m)</title>
          <description>Two doses of MenACWY Ad+ vaccine were to be given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose (one fifth) of MenACWY PS vaccine was to be given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
        <group group_id="E6">
          <title>UK24- (MenACWY Ad- at 2,4m)</title>
          <description>Two doses of MenACWY Ad- vaccine were to be given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was to be given at 12 months of age.</description>
        </group>
        <group group_id="E7">
          <title>CA24- (MenACWY Ad- at 2,4m)</title>
          <description>Two doses of MenACWY Ad- vaccine were to be given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar® at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose (one fifth) of MenACWY PS vaccine was to be given concomitantly with MMR (and Prevnar, if available) at 12 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IDIOPATHIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>CONGENITAL MEGACOLON</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>HYPOSPADIAS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>PLAGIOCEPHALY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>DEVELOPMENTAL DELAY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>FOOD ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>CROUP INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>INFECTED CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>VIRAL RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>BURNS FIRST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>BURNS SECOND DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>LIMB CRUSHING INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>TRAUMATIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>FEBRILE CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>BRONCHIAL HYPERREACTIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ERYTHEMA MULTIFORME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ACROCHORDON EXCISION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>CIRCUMCISION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>HYDROCELE OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>TENDON SHEATH INCISION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="97" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="97" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="90" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="89" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CRYING</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="78" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="84" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="68" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="59" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="45" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="85" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="77" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="82" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>CROUP INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS DIAPER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>RASH PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigators from publishing. Any publications from a single site are postponed until the publication of the pool data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccine and Diagnostics S.r.l</organization>
      <email>RegistryContactVaccineUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

